in GPCR Research Advancements in the use of xenopus oocytes for modelling neurological disease for novel

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

neuropeptides and directs growth, sexual differentiation, and egg production in female Schistosoma mansoni A Novel

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024 The Promise of Oxytocin: Novel

the intricacies of GPCR signaling and utilising advanced assay technologies, researchers can identify novel

drug discovery Confo Therapeutics Appoints Stephen Dowd As Chief Business Officer Septerna Announces Novel

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

analysis, have facilitated drug discovery and design targeting GPCRs, leading to the development of novel

Industry News Domain Therapeutics and Chime Biologics announce manufacturing agreement  to advance novel

and the extracellular loops of D1R, D2LR, and D4R, validating substantial binding affinities to these prime

G-protein coupled receptors Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel

regulation of PLCβ3-catalyzed PIP2 hydrolysis GPCR Binders, Drugs, and more Discovery of Guanfacine as a Novel

Binders, Drugs, and more Identification of 1,3,8-triazaspiro[4.5]decane-2,4-dione Derivatives as a Novel

Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

receptor negative allosteric modulators Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel

G-protein-coupled receptors Reviews, GPCRs, and more RGS proteins and cardiovascular Angiotensin II Signaling: Novel

and Selectively Label Calcium Sensing Receptors In Vitro, In Vivo, and Ex Vivo GPCRs in Neuroscience Novel

John Teye Azietaku for his contributor article on Unveiling GPCR Priming: The Hidden Synergy in Cellular

by merging both orthosteric and allosteric pharmacophores within a single compound, resulting in a novel

signaling and lymphocyte chemotaxis, while retaining angiostatic activity GPR68-ATF4 signaling is a novel

However, the evidence obtained in this study proposes novel molecular mechanisms in which β-arrestin

by merging both orthosteric and allosteric pharmacophores within a single compound, resulting in a novel

., A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis.

Ultimately, these efforts hold the promise of unveiling novel insights into cellular signaling and its